Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Venous Thrombosis 2Neoplasms 2Venous Thromboembolism 1Thromboembolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 74Fluorouracil 31Oxaliplatin 21Leucovorin 21130-nm albumin-bound paclitaxel 17Capecitabine 14Irinotecan 12Albumin-Bound Paclitaxel 10irinotecan sucrosofate 8Radiotherapy 6Taxes 5Erlotinib Hydrochloride 5folfirinox 4rubitecan 3Surgical Procedures, Operative 3Specimen Handling 3Pancreaticojejunostomy 3Neoadjuvant Therapy 3Drug Therapy 3Cisplatin 3Chemotherapy, Adjuvant 3ruxolitinib 2masitinib 2dehydroftorafur 2Saline Solution 2S 1 (combination) 2Paclitaxel 2GV1001 peptide 2Fentanyl 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pancreatic Neoplasms × Nadroparin × Clear all
NCT00312013 2017-03-23

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

GlaxoSmithKline

Phase 3 Completed
503 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms, Venous Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡